Immunotherapy has emerged as a groundbreaking approach in the treatment of various diseases, particularly cancer. Its main premise is to harness the body's immune system to fight off diseases, offering a unique and often more effective alternative to traditional therapies.
Immunotherapy, also known as biologic therapy, involves the use of substances to stimulate or suppress the immune system to help the body fight cancer, infections, and other diseases. Some forms of immunotherapy are also known as targeted therapies because they target specific parts of the immune system.
Immunotherapies can be broadly categorized into active, passive, and hybrid types. Active immunotherapy stimulates the immune system to react against an antigen, while passive immunotherapies involve the administration of immune components, such as antibodies. Hybrid immunotherapies combine these approaches.
Immunotherapy is primarily used in the treatment of cancer, but its potential applications extend much further. It is being explored in the treatment of diseases such as multiple sclerosis, tuberculosis, and HIV/AIDS. The advent of personalized medicine has also opened up opportunities for targeted immunotherapies.
Despite its promise, immunotherapy is not without challenges. Issues such as immune-related adverse events, high costs, and the need for individualized treatment plans pose significant hurdles. However, continuous research and technological advancements promise to address these challenges and expand the scope of immunotherapy.
Immunotherapy represents a significant shift in our approach to treating diseases, with the potential to revolutionize healthcare. As physicians, understanding this dynamic field is essential to provide the best possible care to our patients and navigate the evolving landscape of modern medicine.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation